Shares in Chinese pharmaceutical company BeiGene (NASDAQ: BGNE) are up more than 34% this year, and more than 79% over the past 12 months. The company is coming off a strong first-quarter report, has two potential blockbuster cancer drugs in Brukinsa and Tislelizumab, and has lucrative collaboration projects with Novartis , Amgen , and Bristol Myers Squibb .
In short, there's plenty of fire to back up the optimistic smoke regarding the stock. The Chinese pharmaceutical industry is the second-largest in the world behind the United States, and like the U.S., an aging population in the country is driving increased sales.
Image source: Getty Images.
For further details see:
Is This Chinese Biopharma Stock Still a Buy?